<h3>Purpose/Objective(s)</h3> Radiotherapy is widely used to palliate symptomatic lesions in patients with mesothelioma. However, radiotherapy alone does not improve patient survival. There is currently little published data on radiotherapy and immunotherapy combination in mesothelioma. Here, we aim to optimize a clinically relevant radiotherapy and immunotherapy combination by pre-conditioning tumor microenvironment using low dose radiotherapy for effective immunotherapy responses using mouse model of mesothelioma. <h3>Materials/Methods</h3> Mice were implanted in the flank with 1 × 10^5 murine AB1-HA mesothelioma cells and radiotherapy treatment commenced on day 10 once tumors were approximately 20-30 mm<sup>2</sup>. Treatment was delivered using an X-RAD SmART small animal image-guided precision irradiator at 225 kV X-RAY (HVL 1mm Cu) with a dose rate of 3 Gy/min. Animals were treated with either 0 Gy (sham-irradiation), or as single or multiple doses of either 2 Gy or 6 Gy over the course of five days. Tumors were harvested two weeks following radiotherapy to assess vessel morphology, T cell infiltration by immunohistochemistry and gene expression using RNA-sequencing. In subsequent experiments, the combination of immunotherapy (anti-PD-1 and anti-CTLA-4) with radiotherapy (2 Gy × 5) were administered concurrently and after radiotherapy as one day and six days apart after the final dose. <h3>Results</h3> Radiotherapy did not change the blood vessel density, pericyte coverage and the basement of the blood vessels (collagen-IV) between sham- and radiotherapy treated groups, suggesting the prescribed radiotherapy doses did not damage the blood vessels. Interestingly, the group receiving radiotherapy dose of 2 Gy × 5 had their vessel length and diameter reduced compared with sham-radiotherapy group and these features are similar to normal vessel characteristics. Analysis of tumor tissues revealed significant influx of CD3<sup>+</sup>CD8<sup>+</sup> T cells following radiotherapy done of 2 Gy × 5 compared with sham radiotherapy group. Gene expression analysis demonstrated inflammatory response gene sets such as type I interferon and tumor necrotic factor-alpha were upregulated in group receiving radiotherapy of 2 Gy × 5, compared with sham radiotherapy group indicating tumor microenvironment may have been an inflamed "hot tumor" following radiotherapy. The combination of anti-PD-1 monotherapy with radiotherapy cured 50 % of the tumor bearing mice. This low cure rate was increased to 100% once dual immunotherapy (anti-PD-1/anti-CTLA-4) was administered concurrently with radiotherapy. All cured mice rejected secondary tumor rechallenge, suggesting cured mice may have developed immunological memory. <h3>Conclusion</h3> Our preliminary finding suggests radiotherapy dose of 2 Gy × 5 was optimal to normalize the tumor blood vessels, increased T cell infiltration, and induced transcriptomic changes associated with inflammatory responses, which may sensitize mesothelioma to immunotherapy. The combination of anti-CTLA-4/anti-PD-1 and radiotherapy were required to achieve 100% cure rate.
Read full abstract